GlassScriptPhysician profile
Mary Green
NPI 1417786096
$1,576.28
in general payments reported to CMS, 2019-2025
21 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $233 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.30 |
| Education | $274.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $381.58 | 2024-2025 | Xtandi |
| Janssen Biotech, INC. | $224.82 | 2025 | Erleada, Carvykti, Rybrevant |
| Bioprotect Medical, INC. | $160.96 | 2025 | Bioprotect Balloon Implant System |
| Pfizer INC. | $138.80 | 2024-2025 | |
| Teleflex LLC | $98.83 | 2025 | Barrigel |
| Seagen INC. | $84.99 | 2025 | |
| Merck Sharp & Dohme LLC | $73.44 | 2024-2025 | Keytruda |
| Coloplast Corp | $60.45 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.24 | 2025 | |
| Novartis Pharmaceuticals Corporation | $43.72 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $35.07 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.21 | 2025 | Fruzaqla |
| Medtronic, INC. | $28.36 | 2025 | Interstim |
| Vertex Pharmaceuticals Incorporated | $26.14 | 2025 | |
| Sumitomo Pharma America, INC. | $24.05 | 2025 | Orgovyx |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21.71 | 2025 | Spaceoar Vue System - 10ml |
| Tolmar, INC. | $21.28 | 2025 | Eligard, Jatenzo |
| Immunitybio, INC. | $20.35 | 2024 | |
| Dendreon Pharmaceuticals LLC | $20.09 | 2025 | Provenge |
| Abbott Laboratories | $18.88 | 2024 | Proclaim |
| Daiichi Sankyo INC. | $13.31 | 2024 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.